Fly News Breaks for March 5, 2015
BMY
Mar 5, 2015 | 06:58 EDT
JPMorgan raised its price target for shares of Bristol-Myers to $75 after the company received FDA approval of Opdivo in lung cancer earlier than expected. The firm sees "rapid adoption" of the drug and notes Bristol has a number of pipeline catalysts remaining in 2015. It reiterates an Overweight rating on the stock.
News For BMY From the Last 2 Days